Dialysis Market Analysis
Source: https://www.fortunebusinessinsights.com/jp/%E9%80%8F%E6%9E%90%E5%B8%82%E5%A0%B4-102367
Market Overview
The global dialysis market was valued at USD 103.15 billion in 2025 and is projected to grow from USD 109.66 billion in 2026 to USD 220.51 billion by 2034, exhibiting a CAGR of 9.12% during the forecast period (2026–2034). The market's sustained expansion is primarily driven by the rising global burden of chronic kidney disease (CKD) and end-stage renal disease (ESRD), growing accessibility to renal care facilities, and rapid advancements in dialysis technologies.
Key Market Segments
By Type
- Services dominate the market, accounting for 77.84% of total share in 2026, fueled by expanding networks of well-equipped renal care centers globally and rising patient volumes.
- Products are also witnessing steady growth, supported by increasing regional manufacturers catering to demand for advanced consumables and equipment.
By Dialysis Type
- Hemodialysis leads significantly, contributing 89.38% of market share in 2026. Its dominance is attributed to widespread clinical availability, efficiency, adoption of arteriovenous (AV) fistula techniques, and higher preference among healthcare professionals for elderly and severe CKD patients.
- Peritoneal Dialysis is the faster-growing modality, driven by its cost-effectiveness, greater patient independence, and rising home dialysis adoption. Home dialysis use rose from 14.8% in 2016 to 20% in 2021 among end-stage kidney disease patients, with peritoneal dialysis accounting for more than 90% of that growth.
By End User
- Dialysis Centers & Hospitals account for 83.13% of market share in 2026, driven by favorable reimbursement policies, rising CKD/ESRD patient volumes, and growing healthcare expenditure.
- Home Care is the fastest-growing end-user segment, propelled by cost advantages, next-generation portable devices, and government initiatives promoting at-home renal care.
Market Drivers
- Rising prevalence of CKD and ESRD: According to the USRDS 2023 annual report, there were 808,536 prevalent ESRD patients in the U.S. in 2021. Globally, chronic kidney failures reached approximately 4.8 million in 2022 and are expected to increase by 3–6% annually.
- Shift toward home dialysis: The American Society of Nephrology reported that home dialysis use increased from 14.8% in 2016 to 20% in 2021 among ESKD patients, supported by new payment models and portable device approvals.
- Expanding renal care infrastructure: Investments in dialysis center networks across emerging economies — including India, China, and Mexico — are increasing patient access and driving revenue growth.
Market Restraints
- Risks and complications associated with both hemodialysis (fluid/electrolyte imbalance, cardiovascular complications) and peritoneal dialysis (peritonitis, hernia risk) may limit adoption.
- Preference for kidney transplantation over long-term dialysis therapy among patients seeking better quality of life remains a challenge.
Regional Insights
| Region | Key Highlights |
|---|
| North America | Largest region with 40.41% share in 2025; U.S. market projected to reach USD 40.67 billion by 2026. High ESRD prevalence and strong reimbursement infrastructure are primary drivers. |
| Europe | Second-largest region; Germany projected at USD 6.4 billion and UK at USD 4.77 billion by 2026. Italy alone had 46,813 patients on dialysis in 2022, with free-of-cost public treatments. |
| Asia Pacific | Fastest-growing region; Japan at USD 6.04 billion, China at USD 7.84 billion, and India at USD 3.12 billion projected by 2026. Public funding and expanding healthcare infrastructure are key growth enablers. |
| Latin America & MEA | Moderate but consistent growth, driven by increasing CKD incidence in Brazil and the entry of international players into the Middle East & Africa. |
Competitive Landscape
The market is semi-consolidated, with major players including:
- Fresenius Medical Care AG & Co. KGaA (Germany)
- DaVita Inc. (U.S.)
- Baxter (U.S.)
- B. Braun SE (Germany)
- Medtronic (Ireland)
- NIPRO (Japan)
- Asahi Kasei Medical Co., Ltd. (Japan)
- Diaverum (Sweden)
Key strategic developments include Fresenius Medical Care's FDA 510(k) clearance for the VersiPD Cycler portable peritoneal dialysis system (April 2022), Baxter's launch of Sharesource Analytics 1.0 for home PD management (June 2021), and Life Healthcare's acquisition of 51 Fresenius renal dialysis clinics in Southern Africa (May 2023).
Outlook
The global dialysis market is set for robust growth through 2034, underpinned by an aging world population, increasing diabetes and hypertension comorbidities, technological innovation in wearable and home-based devices, and government initiatives expanding affordable renal care access across both developed and emerging economies.